ABSTRACT The objective of the study was to conduct a systematic review to synthesize the current evidence on the accuracy of IgM and IgA to early diagnosis the dengue virus. The review protocol was registered at PROSPERO (CRD 42015024808). We searched for studies in the following electronic database from 1990 to January 2018. The search identified 3507 studies. Five studies were included for quantitative analysis. Three studies included evaluations of salivary IgM provided a sensitivity of 86% and specificity of 93%. Two studies included evaluating of IgA salivary showed a combined sensitivity of 69% and a combined specificity of 98%. Despite the results found and the low methodological quality of the studies included in the meta-analysis it is still soon to claim that IgA is better than IgM to diagnosis Dengue.

O objetivo deste trabalho foi avaliar a acurácia da mesotelina como um biomarcador para o câncer de ovário. Realizou-se uma revisão sistemática quantita tiva. Uma pesquisa global nas bases de dados Medline, LILACS, SCOPUS, Embase, Cochrane Central Register of Controlled Trials, Biomed Central, e ISI Web of Science foi realizada de janeiro de 1990 a junho de 2015. Para a inclusão nesta revisão sistemática, os estu dos deveriam ter mensurado os níveis mesotelina em pelo menos dois diagnósticos histológicos; câncer de ovário (câncer de ovário ou limítrofe) vs. tumores de ovário benignos ou normais. Para cada estudo foram construídas tabelas de contingência 2 x 2. Calculou-se a sensibilidade, especificidade e odds ratio diagnóstica globais. A qualidade dos estudos foi realizado de acordo com o QUADAS-2. A análise estatística foi realizada com o software Stata 11, Meta-DiSc(r) e RevMan 5.2. Doze estudos foram realizados incluindo 1.561 mulhe res. A sensibilidade agrupada foi de 0,62 (IC 95% 0,58-0,66) e a especificidade foi de 0,94 (IC 95% 0,92-0,95). A DOR foi 38,92 (IC 95% 17,82-84,99). Nossa revisão sistemática mostrou que a mesotelina não pode servir como um biomarcador isolado para o câncer de ovário.

The objective of this work was to estimate the accuracy of mesothelin as a biomarker for ovarian cancer. A quantitative systematic review was performed. A comprehensive search of the Medline, LILACS, SCOPUS, Embase, Cochrane Central Register of Controlled Trials, Biomed Central, and ISI Web of Science databases was conducted from January 1990 to June 2015. For inclusion in this systematic review, the papers must have measured mesothelin levels in at least two histological diagnoses; ovarian cancer (borderline or ovarian tumor) vs. benign or normal ovarian tissue. For each study, 2 x 2 contingency tables were constructed. We calculated the sensitivity, specificity and diagnostic odds ratio. The verification bias was performed according to QUADAS-2. Statistical analysis was performed with the software Stata 11, Meta-DiSc(r) and RevMan 5.2. Twelve studies were analyzed, which included 1,561 women. The pooled sensitivity was 0.62 (CI 95% 0.58 - 0.66) and specificity was 0.94 (CI 95% 0.92 - 0.95). The DOR was 38.92 (CI 95% 17.82 - 84.99). Our systematic review shows that mesothelin cannot serve alone as a biomarker for the detection of ovarian cancer.